Matches in Wikidata for { <http://www.wikidata.org/entity/Q59327464> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q59327464 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59327464 description "wetenschappelijk artikel" @default.
- Q59327464 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q59327464 name "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 name "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 type Item @default.
- Q59327464 label "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 label "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 prefLabel "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 prefLabel "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 P1433 Q59327464-86B02712-72F4-49C4-AA94-904D4AEA4B0D @default.
- Q59327464 P1476 Q59327464-7DCA622C-A6D0-4BED-B8F4-ACA7C1BDB4B7 @default.
- Q59327464 P2093 Q59327464-63C01512-678D-492A-9D6D-716F263FFFB6 @default.
- Q59327464 P2093 Q59327464-75C79AF9-F47D-4247-B020-0571804B5FDF @default.
- Q59327464 P2093 Q59327464-87D6B9E5-06C3-4601-9A06-4599D6623DE5 @default.
- Q59327464 P2093 Q59327464-D03F52A9-445D-43C8-A33C-F913BAA684F5 @default.
- Q59327464 P2093 Q59327464-FF131305-E22E-4435-9B11-4ED8BC53C41E @default.
- Q59327464 P275 Q59327464-ae74764f-dd4b-479a-841b-d94e86dcc667 @default.
- Q59327464 P304 Q59327464-12110F5F-72D0-4447-9F3A-C992C9096A1F @default.
- Q59327464 P31 Q59327464-898AB184-AD3F-4A7B-86A0-41ADCC0AF55E @default.
- Q59327464 P356 Q59327464-FFA4DD9F-3E15-456E-BE34-1D345AE214E1 @default.
- Q59327464 P433 Q59327464-2DE4E3A7-A88F-4ADB-83FF-23673453AF4E @default.
- Q59327464 P478 Q59327464-D74531B5-9B82-4727-9BCD-408F5E03B753 @default.
- Q59327464 P50 Q59327464-98207EAA-4830-46D6-B0C3-FDCF13EEA59A @default.
- Q59327464 P50 Q59327464-F857DEC3-5097-4BF6-81E0-2DECCC84D0E1 @default.
- Q59327464 P577 Q59327464-6E4D62CE-A7E1-4D04-BAD5-97D922CADEC0 @default.
- Q59327464 P6216 Q59327464-184364b9-8953-4239-92f3-a57c1d991ab3 @default.
- Q59327464 P921 Q59327464-903A8999-D624-46FB-8978-C6A5AABD2D7F @default.
- Q59327464 P921 Q59327464-FCDD9A3E-871B-4F12-96D2-7A38F835249F @default.
- Q59327464 P932 Q59327464-180AB671-5058-415F-8F89-714CD06E1FBD @default.
- Q59327464 P356 OFY210.2091 @default.
- Q59327464 P1433 Q27725953 @default.
- Q59327464 P1476 "2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance" @default.
- Q59327464 P2093 "Brian A Potoski" @default.
- Q59327464 P2093 "Ghady Haidar" @default.
- Q59327464 P2093 "M Hong Nguyen" @default.
- Q59327464 P2093 "Rachel V Marini" @default.
- Q59327464 P2093 "Ryan K Shields" @default.
- Q59327464 P275 Q24082749 @default.
- Q59327464 P304 "S729-S729" @default.
- Q59327464 P31 Q13442814 @default.
- Q59327464 P356 "10.1093/OFID/OFY210.2091" @default.
- Q59327464 P433 "suppl_1" @default.
- Q59327464 P478 "5" @default.
- Q59327464 P50 Q73186070 @default.
- Q59327464 P50 Q96642108 @default.
- Q59327464 P577 "2018-11-01T00:00:00Z" @default.
- Q59327464 P6216 Q50423863 @default.
- Q59327464 P921 Q31856 @default.
- Q59327464 P921 Q643839 @default.
- Q59327464 P932 "6255415" @default.